Get started
Work

Weight Gain During Successful Tuberculosis Treatment Increases the Risk of Post-tuberculosis Metabolic Syndrome

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Little is known about the relationship between weight gain during treatment and the subsequent risk of cardiovascular and metabolic (cardiometabolic) diseases. We assessed the relationship between changes in body mass index (BMI) during tuberculosis (TB) treatment and prevalence of post-TB metabolic syndrome, a strong predictor of cardiometabolic diseases. Methods: We enrolled a prospective cohort of individuals successfully treated for TB disease in Tbilisi, Georgia, from 2019 to 2022. Eligible participants were HIV-negative individuals aged ≥16 years with newly diagnosed and laboratory-confirmed pulmonary TB. The primary exposure was relative change in BMI from treatment initiation to treatment completion, dichotomized at a ≥5% relative increase. Our primary study outcome was prevalence of post-TB metabolic syndrome (≥3 of the following: elevated blood pressure, elevated triglycerides, low high-density lipoprotein, elevated glycated hemoglobin [HbA1c], and abdominal obesity) at any study visit (including the end of treatment, 6 months post-TB treatment, and 12 months post-TB treatment). Multilevel models were used to estimate the effect of BMI change on post-TB metabolic syndrome. Results: Among 120 participants, the adjusted risk of having metabolic syndrome after TB treatment among those with a ≥5% relative increase in BMI was 2.1 times (95% CI, 1.1-4.0) the risk of those with a <5% relative increase in BMI during treatment. Additionally, the adjusted mean of post-TB HbA1c among those with a ≥5% relative increase in BMI was 0.4 (95% CI, 0.0-0.7) points higher compared with those with a <5% relative increase in BMI. Conclusions: Among individuals who were successfully treated, individuals who had a ≥5% increase in BMI during TB treatment had a significantly increased risk of metabolic syndrome and higher HbA1c levels up to 12 months after TB treatment.
DOI: 10.1093/ofid/ofag620
Authors: Argita D Salindri, Teona Avaliani, Mariam Gujabidze, Leila Goginashvili, Sergo Vashakidze, Zaza Avaliani, Sara C Auld, Jeffrey M Collins, Jason R Andrews, Russell R Kempker, Hardy Kornfeld, Maia Kipiani, Matthew J Magee
Institutions: Emory University, Georgia State University, Stanford Medicine, Stanford University, National Center for Tuberculosis and Lung Disease, University of Georgia, European University, University of Massachusetts Chan Medical School, David Tvildiani Medical University
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,053
Awards: Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor), Latent tuberculosis infection and risk of type 2 diabetes mellitus in US veterans, Pulmonary impairment after tuberculosis in Georgia: Enhancing clinical research capacity to address the intersection of non-communicablediseases and tuberculosis, An Exploratory Study of Anti-Tuberculosis Drug Penetration into Cerebrospinal Fluid, Emory/Georgia TB Research Advancement Center (TRAC), Immunometabolic impact of stress hyperglycemia on tuberculosis treatment outcomes and risk of diabetes mellitus, Emory-Georgia TB Research Training Program
OpenAlex ID: W7215058292
FWCI: 4.012
Cites: 31
Cited by: 1
Related to: 10